Last reviewed · How we verify
Calcium Dobesilate group
Calcium Dobesilate, marketed by The Affiliated Hospital of Xuzhou Medical University, holds a niche position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent, which helps maintain its competitive edge. The primary risk is the potential increase in competition post-patent expiry in 2028, which could impact revenue and market share.
At a glance
| Generic name | Calcium Dobesilate group |
|---|---|
| Also known as | Treatment group |
| Sponsor | The Affiliated Hospital of Xuzhou Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (PHASE1, PHASE2)
- Post-operative Methylprednisolone Taper Course for Orthopedic Surgery (PHASE4)
- Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (PHASE2)
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (PHASE2)
- Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |